Skip to main content
Evidence Snapshot

Bile acid receptor

CHEMBL2047 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:04:59Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2047
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bile acid receptor as ChEMBL target CHEMBL2047, mapped to UniProt Q96RI1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bile acid receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2047
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96RI1
Bile acid receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Bile acid receptor matters

As of 2026-09-13

Bile acid receptor is reviewed as Bile acid receptor (UniProt Q96RI1); Bile acid receptor shows approved-linked disease relevance led by primary biliary cirrhosis. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 17 approved drugs, 4972 compounds, and 1004 assays, with lead potency reaching pChEMBL 10.3.

Disease context
primary biliary cirrhosis

Bile acid receptor shows approved-linked disease relevance led by primary biliary cirrhosis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CILOFEXOR, OBETICHOLIC ACID, TROPIFEXOR.

Start review with primary biliary cirrhosis because it currently carries approved-linked support. Linked drugs include CILOFEXOR, OBETICHOLIC ACID, TROPIFEXOR, URSODIOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 17 approved drugs, 4972 compounds, and 1004 assays for this target. The dominant activity type is EC50. CHEMBL4783205 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL4783205 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
17 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Bile acid receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q96RI1, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why primary biliary cirrhosis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4972
Total Compounds
1004
Total Assays
17
Approved Drugs
IC50: 568.0, KI: 2.0, EC50: 4285.0, KD: 8.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4783205
 10.3 IC50 —
No preferred name
CHEMBL4453417
 10.3 IC50 —
No preferred name
CHEMBL4169596
 10.3 IC50 —
No preferred name
CHEMBL4749439
 10.2 IC50 —
No preferred name
CHEMBL4162312
 10.2 IC50 —

Approved Drugs

Structure Compound First Approval
ODEVIXIBAT
CHEMBL4297588
 2021
OBETICHOLIC ACID
CHEMBL566315
 2016
FULVESTRANT
CHEMBL1358
 2002
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:04:59Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2047